Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 161/Tozinameran vaccine - BioNTech/Pfizer

Next Previous
Drug Profile

BNT 161/Tozinameran vaccine - BioNTech/Pfizer

Alternative Names: BNT162b2/BNT161 combination vaccine; Combination COVID-19 & Influenza - BioNTech/Pfizer; mRNA-based combination vaccine - BioNTech/Pfizer; PF-07926307; Tozinameran/BNT-161 vaccine - BioNTech/Pfizer; Tozinameran/qIRV - BioNTech/Pfizer

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech; Pfizer
  • Class COVID-19 vaccines; Influenza virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections; Influenza virus infections

Most Recent Events

  • 11 Feb 2025 BioNTech plans a phase I/II trial for COVID-2019 infections and Influenza virus infections (Monotherapy, Combination therapy, Prevention) in USA (IM) in February 2025 (NCT06821061)
  • 10 Feb 2025 BioNTech initiates a phase I/II trial for COVID-2019 infections and Influenza virus infections (Prevention) in USA (IM) (NCT06821061)
  • 26 Nov 2024 BioNTech SE and Pfizer completes a phase III trial in Influenza virus infections and COVID-2019 infections prevention (In volunteers) in USA (NCT06178991)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top